<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198884</url>
  </required_header>
  <id_info>
    <org_study_id>16-1108-100C</org_study_id>
    <nct_id>NCT03198884</nct_id>
  </id_info>
  <brief_title>A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir</brief_title>
  <official_title>A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Illinois Healthcare Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Illinois Healthcare Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of
      Darunavir, Ritonavir, and Dolutegravir
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIV RNA quantitative testing (serum)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Percentage of subjects with &lt; 20 copy RNA at 48 weeks</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV-1-infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult HIV positive patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years old

          -  Received a regimen of darunavir 800 mg/ritonavir 100 mg in combination with
             dolutegravir 50 mg QD for ≥24 weeks as documented in EMR

          -  Laboratory reports (CD4, viral load, SrCr) available at time points +/- 4 6 weeks from
             12, 24, 36, 48 weeks from start of regimen

          -  Resistance data (if applicable)

        Exclusion Criteria:

          -  Received a regimen of darunavir/ritonavir in combination with dolutegravir for &lt;24
             weeks duration

          -  Patients receiving darunavir/ritonavir + DTG+NRTI's

          -  Missing laboratory data in ≥2 study time points

          -  Patients missing more than five doses over two weeks prior study visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern Illinois Healthcare Foundation</investigator_affiliation>
    <investigator_full_name>John Verna</investigator_full_name>
    <investigator_title>Physician Assistant</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

